Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Shares Outstanding (Weighted Average) (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $40.9 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Shares Outstanding (Weighted Average) rose 1.58% year-over-year to $40.9 million, compared with a TTM value of $40.9 million through Sep 2024, up 1.58%, and an annual FY2023 reading of $40.3 million, up 3.38% over the prior year.
  • Shares Outstanding (Weighted Average) was $40.9 million for Q3 2024 at Oramed Pharmaceuticals, roughly flat from $41.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $41.0 million in Q2 2024 and bottomed at $38.7 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 3 years is $39.9 million, with a median of $40.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 3.85% in 2023, then rose 1.58% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $39.0 million in 2022, then grew by 3.38% to $40.3 million in 2023, then grew by 1.41% to $40.9 million in 2024.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ORMP at $40.9 million in Q3 2024, $41.0 million in Q2 2024, and $40.8 million in Q1 2024.